Table 5.
Analyzed pathways of the potential target
| Term | Count | % | P-value |
|---|---|---|---|
| Neuroactive ligand–receptor interaction | 28 | 0.7718 | 2.33E-11 |
| Pathways in cancer | 26 | 0.7166 | 1.25E-07 |
| Bladder cancer | 10 | 0.2756 | 4.18E-07 |
| Calcium signaling pathway | 18 | 0.4961 | 6.48E-07 |
| Prostate cancer | 12 | 0.3308 | 6.68E-06 |
| ALS | 9 | 0.2481 | 2.95E-05 |
| Non-small-cell lung cancer | 9 | 0.2481 | 3.39E-05 |
| Glioma | 9 | 0.2481 | 1.06E-04 |
| Small-cell lung cancer | 10 | 0.2756 | 1.49E-04 |
| Colorectal cancer | 10 | 0.2756 | 1.49E-04 |
| Gap junction | 10 | 0.2756 | 2.33E-04 |
| Pancreatic cancer | 9 | 0.2481 | 2.73E-04 |
| VEGF signaling pathway | 9 | 0.2481 | 3.63E-04 |
| Metabolism of xenobiotics by cytochrome P450 | 8 | 0.2205 | 4.93E-04 |
| Drug metabolism | 8 | 0.2205 | 6.03E-04 |
| Progesterone-mediated oocyte maturation | 9 | 0.2481 | 9.17E-04 |
| T-cell receptor signaling pathway | 10 | 0.2756 | 9.80E-04 |
| Insulin signaling pathway | 11 | 0.3032 | 0.001285 |
| Prion diseases | 6 | 0.1654 | 0.001287 |
| Melanoma | 8 | 0.2205 | 0.001367 |
| GnRH signaling pathway | 9 | 0.2481 | 0.002145 |
| Focal adhesion | 13 | 0.3583 | 0.002765 |
| NOD-like receptor signaling pathway | 7 | 0.1929 | 0.003321 |
| ErbB signaling pathway | 8 | 0.2205 | 0.004394 |
| Thyroid cancer | 5 | 0.1378 | 0.004572 |
| Type II diabetes mellitus | 6 | 0.1654 | 0.004846 |
| Alzheimer’s disease | 11 | 0.3032 | 0.005136 |
| Endometrial cancer | 6 | 0.1654 | 0.007473 |
| Arginine and proline metabolism | 6 | 0.1654 | 0.008098 |
| Neurotrophin signaling pathway | 9 | 0.2481 | 0.008989 |
| Toll-like receptor signaling pathway | 8 | 0.2205 | 0.009847 |
| Arachidonic acid metabolism | 6 | 0.1654 | 0.010189 |
| Graft-versus-host disease | 5 | 0.1378 | 0.013197 |
| Oocyte meiosis | 8 | 0.2205 | 0.015298 |
| Vascular smooth muscle contraction | 8 | 0.2205 | 0.016754 |
| Apoptosis | 7 | 0.1929 | 0.016888 |
| p53 signaling pathway | 6 | 0.1654 | 0.022214 |
| Renal cell carcinoma | 6 | 0.1654 | 0.024849 |
| Cell cycle | 8 | 0.2205 | 0.028683 |
| Glutathione metabolism | 5 | 0.1378 | 0.030289 |
| Fc epsilon RI signaling pathway | 6 | 0.1654 | 0.037359 |
| MAPK signaling pathway | 12 | 0.3308 | 0.0418 |
Abbreviations: ALS, amyotrophic lateral sclerosis; NOD, nucleotide oligomerization domain; VEGF, vascular endothelial growth factor; MAPK, mitogen-activated protein kinase.